pharma news today glp-1 obesity drug Some US employers to drop coverage of drugs in 2027 as use increases The Next Big Weight Loss

Both medicines are administered as subcutaneous injections, typically once weekly, and are still undergoing large-scale clinical trials

The safest editorial rule is direct: describe what researchers examined, cite the source, and avoid expanding the finding beyond the model

These treatments may benefit you if you struggle with low energy, poor focus, or slow metabolism

For example, empagliflozin suppresses the activation and infiltration of auto-aggressive CXCR6 + CD8 + T cells through ketogenesis-dependent mechanisms (177)

In our study using June 2024 data on fee-for-service Medicaid in 50 states and Washington, D.C., only 13 covered GLP-1s for weight loss in adults